InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
51 hedge funds and large institutions have $32.9M invested in InVivo Therapeutics Holdings Corp in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 2 reducing their positions, and 2 closing their positions.
450% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 2
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
13% more funds holding
Funds holding: 45 → 51 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
35% less capital invested
Capital invested by funds: $50.4M → $32.9M (-$17.5M)
91% less call options, than puts
Call options by funds: $35K | Put options by funds: $409K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$715K |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$626K |
| 3 |
Millennium Management
New York
|
+$536K |
| 4 |
Morgan Stanley
New York
|
+$536K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$268K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WF
Welch & Forbes
Boston,
Massachusetts
|
-$1.34M |
| 2 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$700K |
| 3 |
Goldman Sachs
New York
|
-$447K |
| 4 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$183K |
| 5 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
-$27K |
NVIV Hedge Fund Activity: Q4 2016 in Review
51 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q4 2016, worth a combined $32.9M — down 35% from $50.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NVIV positions and 2 closed out — a net gain of 6 holders — while 11 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $715K. The largest seller was Welch & Forbes, cutting an estimated $1.34M.
- 51 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q4 2016, up from 45 in Q3 2016.
- Funds reported $32.9M of InVivo Therapeutics Holdings Corp stock for Q4 2016, down 35% quarter-over-quarter.
- 8 funds opened new InVivo Therapeutics Holdings Corp positions in Q4 2016 and 2 closed out, a net change of +6 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $715K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q4 2016 was Welch & Forbes, an estimated $1.34M sold.
Based on aggregated 13F filings for Q4 2016.